Contaminants in heparins: are all facts known?
作者信息
Fareed Jawed, Hoppensteadt Debra A, Ramacciotti Eduardo, Hull Russell D
出版信息
Clin Appl Thromb Hemost. 2010 Jun;16(3):242-3. doi: 10.1177/1076029610365507.
PMID:20547552
Abstract
摘要
相似文献
1
Contaminants in heparins: are all facts known?
Clin Appl Thromb Hemost. 2010 Jun;16(3):242-3. doi: 10.1177/1076029610365507.
2
Contaminated heparin-affected patient plasmas are associated with activated contact systems.
Clin Appl Thromb Hemost. 2010 Jun;16(3):261-5. doi: 10.1177/1076029610362073.
3
Heparin and oversulfated heparin byproduct induce thrombin generation through contact system activation in plasma of patients with HIT.
Clin Appl Thromb Hemost. 2010 Jun;16(3):251-60. doi: 10.1177/1076029610362072. Epub 2010 May 11.
4
Contaminants in heparin.
Clin Appl Thromb Hemost. 2011 Apr;17(2):125. doi: 10.1177/1076029610397942.
5
Review: contaminants in heparin: review of the literature, molecular profiling, and clinical implications.
Clin Appl Thromb Hemost. 2011 Apr;17(2):126-35. doi: 10.1177/1076029610392214. Epub 2011 Feb 1.
6
Oversulfated heparin by-products induce thrombin generation in human plasmas through contact system activation.
Clin Appl Thromb Hemost. 2010 Jun;16(3):244-50. doi: 10.1177/1076029610362071.
7
[Artificial polysaccharide in contaminated heparin. Acute hypersensitivity reactions explained--but how could it happen?].
Lakartidningen. 2008;105(39):2660-1.
8
Contaminants in heparins continue to be unfolded.
Int Angiol. 2008 Dec;27(6):457-61.
9
The tainted heparin story: an update.
Thromb Haemost. 2009 Nov;102(5):907-11. doi: 10.1160/TH09-02-0079.
10
New and generic anticoagulants and biosimilars: safety considerations.
Clin Appl Thromb Hemost. 2011 Apr;17(2):136-9. doi: 10.1177/1076029610387128. Epub 2010 Dec 15.
引用本文的文献
1
Biosimilars of low molecular weight heparins: Relevant background information for your drug formulary.
Br J Clin Pharmacol. 2019 Nov;85(11):2479-2486. doi: 10.1111/bcp.14081. Epub 2019 Sep 4.
Zotero 插件